{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:41:13Z","timestamp":1785883273663,"version":"3.56.0"},"reference-count":13,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.20055","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T22:08:15Z","timestamp":1612562895000},"page":"29-34","source":"Crossref","is-referenced-by-count":2,"title":["The standardized uptake value calculated from                    &lt;sup&gt;111&lt;\/sup&gt;In-ibritumomab tiuxetan single-photon emission computed                    tomography\/computed tomography is a useful predictor of the clinical response in                    patients treated by &lt;sup&gt;90&lt;\/sup&gt;Y- ibritumomab tiuxetan therapy"],"prefix":"10.3960","volume":"61","author":[{"given":"Ayaka","family":"Kume","sequence":"first","affiliation":[{"name":"Department of Hematology, Asahi General                            Hospital, Chiba, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Toriihara","sequence":"additional","affiliation":[{"name":"PET Imaging Center, Asahi General Hospital,                            Chiba, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Asahi General                            Hospital, Chiba, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Harata","sequence":"additional","affiliation":[{"name":"Department of Radiology, Asahi General                            Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Isogai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Asahi General                            Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Asahi General                            Hospital, Chiba, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Knox                            SJ,                                Goris                            ML,                                Trisler                            K                    <i>et al.<\/i> Yttrium-90-labeled anti-CD20 monoclonal antibody therapy                    of recurrent B-cell lymphoma. Clin Cancer Res. 1996; 2:                    457-470."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Witzig                            TE,                                Gordon                            LI,                                Cabanillas                            F                    <i>et al.<\/i> Randomized controlled trial of yttrium-90-labeled                    ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for                    patients with relapsed or refractory low-grade, follicular, or transformed                    B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002; 20:                    2453-2463.","DOI":"10.1200\/JCO.2002.11.076"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Tobinai                            K,                                Watanabe                            T,                                Ogura                            M                    <i>et al.<\/i> Japanese phase II study of 90 Y-ibritumomab tiuxetan in                    patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 2009;                    100: 158-164.","DOI":"10.1111\/j.1349-7006.2008.00999.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Witzig                            TE,                                Molina                            A,                                Gordon                            LI                    <i>et al.<\/i> Long-term responses in patients with recurring or                    refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab                    tiuxetan. Cancer. 2007; 109: 1804-1810.","DOI":"10.1002\/cncr.22617"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Uike                            N,                                Choi                            I,                                Tsuda                            M                    <i>et al.<\/i> Factors associated with effects of 90Y-ibritumomab                    tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin                    lymphoma: single-institution experience with 94 Japanese patients in rituximab                    era. Int J Hematol. 2014; 100: 386-392.","DOI":"10.1007\/s12185-014-1636-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Tsukamoto                            N,                                Yokohama                            A,                                Higuchi                            T                    <i>et al.<\/i> Tumor long-axis diameter and SUVmax predict long-term                    responders in 90Y-ibritumomab tiuxetan monotherapy. Int J Hematol. 2019; 109:                    91-97.","DOI":"10.1007\/s12185-018-2526-z"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Toriihara                            A,                                Daisaki                            H,                                Yamaguchi                            A                    <i>et al.<\/i> Applying standardized uptake values in                    gallium-67-citrate single-photon emission computed tomography\/computed                    tomography studies and their correlation with blood test results in                    representative organs. Nucl Med Commun. 2018; 39: 720-724.","DOI":"10.1097\/MNM.0000000000000868"},{"key":"8","unstructured":"8 Kaneta                            T,                                Ogawa                            M,                                Daisaki                            H                    <i>et al.<\/i> SUV measurement of normal vertebrae using SPECT\/CT with                    Tc-99m methylene diphosphonate. Am J Nucl Med Mol Imaging. 2016; 6:                    262-268."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Cheson                            BD,                                Fisher                            RI,                                Barrington                            SF                    <i>et al.<\/i> Recommendations for initial evaluation, staging, and                    response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano                    classification. J Clin Oncol. 2014; 32: 3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Solal-C\u00e9ligny                            P,                                Roy                            P,                                Colombat                            P                    <i>et al.<\/i> Follicular lymphoma international prognostic index.                    Blood. 2004; 104: 1258-1265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Kanda                            Y. Investigation                    of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone                    Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Hanaoka                            K,                                Hosono                            M,                                Tatsumi                            Y                    <i>et al.<\/i> Heterogeneity of intratumoral 111In-ibritumomab tiuxetan                    and 18F-FDG distribution in association with therapeutic response in                    radioimmunotherapy for B-cell non-Hodgkin\u2019s lymphoma. EJNMMI Res. 2015; 5:                    10.","DOI":"10.1186\/s13550-015-0093-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Giraudo                            C,                                Karanikas                            G,                                Weber                            M                    <i>et al.<\/i> Correlation between glycolytic activity on [18F]-FDG-PET                    and cell density on diffusion-weighted MRI in lymphoma at staging. J Magn Reson                    Imaging. 2018; 47: 1217-1226.","DOI":"10.1002\/jmri.25884"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/1\/61_20055\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T04:33:54Z","timestamp":1616214834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/1\/61_20055\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20055","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}